CMS launched a voluntary payment model designed to expand Medicare coverage of GLP-1 weight-loss drugs, the agency announced. The model lets participating Medicare plans cover GLP-1s under new payment rules intended to lower patient costs and increase beneficiary access. The program is framed as a policy step tied to broader administration goals to reduce drug prices and broaden obesity treatment access. GLP-1s are glucagon-like peptide-1 receptor agonists used for diabetes and weight loss; the model could reshape payer negotiations and utilization patterns in Medicare.